Trial Profile
A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2018
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Bismuth salicylate
- Indications Gastrointestinal disorders; Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biogen Idec
- 14 Nov 2018 Primary endpoint (Time to first gastrointestinal-related event) has not been met as per results published in the Clinical Therapeutics
- 14 Nov 2018 Results published in the Clinical Therapeutics
- 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.